secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047856
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026
--------------------------------------------------------------------------------

- Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.
- Dismissed Ernst & Young as auditor; engaged Deloitte & Touche for FY 2025; no disagreements reported.
- Phase 2 data for TTI-101 in IPF expected 2H 2025; IND for TTI-109 planned 1H 2025.
- Phase 1 study of TTI-101 in advanced solid tumors published in Clinical Cancer Research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/0001104659-25-047856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer